X

Trial Profile

Prospective Register Study to Record Safety and Efficacy of New Oral Anticoagulants

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
Indications Pulmonary embolism; Stroke; Venous thromboembolism
Focus Adverse reactions; Therapeutic Use
Acronyms DRESDEN NOAC RREGISTRY; NOAC
Sponsors GWT-TUD GmbH

Most Recent Events

17 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
17 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
15 Mar 2022 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com